Treatment of refractory paediatric giardiasis using secnidazole plus albendazole: a case series

Area of Science:

• Infectious Diseases
• Pediatric Medicine
• Pharmacology

Background:

• Giardiasis, caused by Giardia lamblia, is a common intestinal protozoan infection, particularly in children.
• Standard treatments like 5-nitroimidazoles and nitazoxanide can fail, necessitating alternative therapeutic strategies.
• Drug-refractory giardiasis presents a significant clinical challenge, impacting patient health and treatment outcomes.

Purpose of the Study:

• To evaluate the efficacy and tolerability of a combination therapy for pediatric giardiasis.
• To assess the use of secnidazole (SNZ) and albendazole (ABZ) in children with treatment-refractory Giardia infections.
• To provide an alternative treatment option for cases of giardiasis unresponsive to conventional therapies.

Main Methods:

• A cohort of 11 pediatric patients with drug-refractory giardiasis was treated.
• Therapy involved a combination of secnidazole (30 mg/kg/day for 3 days) and albendazole (400 mg daily for 5 days).
• Patient outcomes, including cure rates and side effects, were monitored.

Main Results:

• The combination therapy of secnidazole and albendazole resulted in a cure for 9 out of 11 (82%) pediatric patients.
• The treatment regimen was well-tolerated, with only mild, transient, and self-limited side effects reported.
• No treatment discontinuations were necessary due to adverse events.

Conclusions:

• Secnidazole plus albendazole is a viable and effective alternative treatment for pediatric giardiasis refractory to standard therapies.
• This combination demonstrates a favorable safety profile in the studied pediatric population.
• Further research is warranted to confirm safety and compare this regimen with other combination strategies.